Future Fund LLC Boosts Holdings in Edwards Lifesciences Co. (NYSE:EW)

Future Fund LLC increased its stake in shares of Edwards Lifesciences Co. (NYSE:EW) by 37.8% in the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 15,898 shares of the medical research company’s stock after buying an additional 4,363 shares during the period. Edwards Lifesciences comprises about 3.2% of Future Fund LLC’s holdings, making the stock its 16th biggest position. Future Fund LLC’s holdings in Edwards Lifesciences were worth $1,074,000 as of its most recent filing with the SEC.

A number of other large investors have also added to or reduced their stakes in the stock. Crewe Advisors LLC purchased a new position in shares of Edwards Lifesciences in the first quarter worth about $28,000. First Community Trust NA purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $29,000. Webster Bank N. A. purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $39,000. Versant Capital Management Inc increased its stake in shares of Edwards Lifesciences by 206.3% in the second quarter. Versant Capital Management Inc now owns 484 shares of the medical research company’s stock worth $45,000 after purchasing an additional 326 shares in the last quarter. Finally, HHM Wealth Advisors LLC purchased a new position in shares of Edwards Lifesciences in the second quarter worth about $55,000. Hedge funds and other institutional investors own 79.46% of the company’s stock.

Analyst Ratings Changes

EW has been the subject of several recent research reports. Deutsche Bank Aktiengesellschaft reduced their target price on shares of Edwards Lifesciences from $103.00 to $85.00 and set a “buy” rating for the company in a research note on Thursday, July 25th. Morgan Stanley reaffirmed an “equal weight” rating and set a $70.00 price objective on shares of Edwards Lifesciences in a research note on Friday, October 11th. Oppenheimer reaffirmed an “outperform” rating and set a $90.00 price objective on shares of Edwards Lifesciences in a research note on Thursday, September 12th. Baird R W cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Thursday, July 25th. Finally, Daiwa America cut shares of Edwards Lifesciences from a “strong-buy” rating to a “hold” rating in a research note on Wednesday, October 30th. Seventeen research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and an average price target of $75.67.

Insider Activity at Edwards Lifesciences

In other Edwards Lifesciences news, insider Larry L. Wood sold 25,000 shares of the business’s stock in a transaction on Tuesday, November 5th. The shares were sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the transaction, the insider now directly owns 198,526 shares of the company’s stock, valued at approximately $13,084,848.66. The trade was a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. In other news, VP Daveen Chopra sold 1,250 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $69.95, for a total value of $87,437.50. Following the sale, the vice president now directly owns 29,333 shares of the company’s stock, valued at $2,051,843.35. This represents a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Larry L. Wood sold 25,000 shares of the company’s stock in a transaction dated Tuesday, November 5th. The stock was sold at an average price of $65.91, for a total transaction of $1,647,750.00. Following the completion of the sale, the insider now directly owns 198,526 shares in the company, valued at $13,084,848.66. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 36,250 shares of company stock worth $2,416,588 in the last three months. 1.27% of the stock is owned by insiders.

Edwards Lifesciences Trading Down 1.3 %

NYSE:EW opened at $65.81 on Wednesday. The company has a fifty day moving average of $67.53 and a 200 day moving average of $76.65. Edwards Lifesciences Co. has a 52 week low of $58.93 and a 52 week high of $96.12. The company has a quick ratio of 2.89, a current ratio of 3.46 and a debt-to-equity ratio of 0.06. The firm has a market capitalization of $38.81 billion, a P/E ratio of 9.50, a P/E/G ratio of 3.75 and a beta of 1.12.

Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings results on Thursday, October 24th. The medical research company reported $0.67 EPS for the quarter, meeting analysts’ consensus estimates of $0.67. Edwards Lifesciences had a net margin of 70.82% and a return on equity of 20.76%. The company had revenue of $1.35 billion during the quarter, compared to analyst estimates of $1.57 billion. During the same period in the prior year, the business posted $0.59 EPS. The firm’s revenue was up 8.9% compared to the same quarter last year. On average, research analysts predict that Edwards Lifesciences Co. will post 2.57 earnings per share for the current year.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.